Sepsis and Septic Shock — Early Management

Key Points

• Septic shock and probable or definite sepsis require immediate antimicrobials, ideally within 1 hour of recognition.
• Possible sepsis without shock allows a rapid focused diagnostic assessment when infection probability is uncertain.
• Use balanced crystalloids for initial resuscitation and reassess fluid responsiveness and tolerance frequently.
• The 30 mL/kg early fluid recommendation is a starting framework for hypoperfusion or shock, not permission to ignore overload or response.
• Norepinephrine is first-line vasopressor therapy and can be started peripherally when necessary to avoid delay.
• A MAP near 65 mm Hg is a common starting target, then individualize to perfusion.
• Source control and antimicrobial therapy should proceed in parallel.
• Screening tools supplement clinical judgment; the 2026 guideline does not support qSOFA as the sole screening approach.

Algorithm

1. Recognize suspected infection plus organ dysfunction and assess shock, oxygenation, mentation, perfusion, and likely source.
2. Obtain cultures and lactate promptly when indicated, but do not delay needed antimicrobials.
3. Give immediate broad-spectrum antimicrobials for shock or probable/definite sepsis and use rapid assessment for uncertain possible sepsis without shock.
4. Begin balanced crystalloid for hypoperfusion in reassessed aliquots, using roughly 30 mL/kg over 3 hours as an initial severe-hypoperfusion framework.
5. Start norepinephrine promptly if hypotension persists or fluids are unsafe or inadequate, including through appropriate peripheral access if needed.
6. Reassess capillary refill, mentation, urine output, lung findings, blood pressure, lactate trend, and ultrasound or dynamic fluid measures.
7. Add vasopressin or other vasopressor support and consider hydrocortisone for refractory shock according to ICU protocol.
8. Obtain definitive source control and narrow antimicrobials as culture and diagnostic information become available.

Clinical Synopsis & Reasoning

Suspect sepsis when infection is accompanied by new organ dysfunction such as altered mental status, hypotension, hypoxemia, oliguria, thrombocytopenia, rising bilirubin or creatinine, lactate elevation, or other evidence of impaired perfusion. Sepsis is not defined by fever or leukocytosis alone, and normal vital signs early in disease do not reliably exclude it. Identify likely sources including lung, urinary tract, abdomen, skin and soft tissue, devices, CNS, and bloodstream while evaluating noninfectious mimics.

The 2026 Surviving Sepsis Campaign distinguishes urgency according to the probability and severity of infection. Patients with septic shock, or probable or definite sepsis, should receive antimicrobials immediately, ideally within 1 hour of recognition. For possible sepsis without shock, a rapid time-limited evaluation for infectious versus noninfectious causes can reduce unnecessary antibiotic exposure, with treatment initiated promptly if concern persists. Blood cultures should be obtained before antibiotics when this does not meaningfully delay treatment.

Lactate is a useful risk and perfusion marker but is neither specific nor required for diagnosis. Physical examination of mentation, capillary refill, skin temperature, urine output, and blood pressure remains essential. Point-of-care cardiac and lung ultrasound can help distinguish vasodilatory shock from major ventricular dysfunction or fluid intolerance. Source control, such as drainage of an abscess or relief of an obstructed infected collecting system, is a parallel emergency rather than a late step.

Treatment Strategy & Disposition

For sepsis-induced hypoperfusion or septic shock, 2026 guidance supports at least 30 mL/kg of IV crystalloid over the first 3 hours as an initial framework, with individualization and repeated reassessment. Balanced crystalloids are generally preferred. Patients with heart failure, kidney disease, cirrhosis, pulmonary edema, or rapidly improving perfusion may require smaller aliquots and earlier vasopressors rather than blind completion of a fixed volume.

Norepinephrine is first-line vasopressor therapy for septic shock. Peripheral initiation through a well-sited proximal IV can be appropriate to avoid dangerous delays while central access is arranged if needed. A common initial mean arterial pressure target is about 65 mm Hg, adjusted to the patient's perfusion and comorbidities. Add vasopressin when norepinephrine requirements rise; epinephrine is another escalation option. Persistent shock despite fluids and vasopressors may warrant IV hydrocortisone according to current critical-care guidance.

Antimicrobial choice must match likely source, local resistance patterns, prior cultures, immune status, and healthcare exposures, then narrow when microbiology clarifies the diagnosis. Reassess daily for de-escalation. Early source control should occur as soon as medically and logistically practical. Admit patients with organ dysfunction or shock to a monitored setting, and coordinate ICU care when vasopressors, invasive ventilation, or other organ support is required.

Epidemiology / Risk Factors

• Sepsis can arise from community, healthcare-associated, or opportunistic infections and affects all age groups.
• Older age, immunocompromise, malignancy, chronic organ disease, invasive devices, recent hospitalization, and frailty increase risk.
• Pneumonia, urinary infection, intra-abdominal infection, and bloodstream infection are common sources.
• Antimicrobial resistance and local epidemiology materially affect empiric regimen selection.
• Survivors can experience prolonged physical, cognitive, and psychological consequences after discharge.

Investigations

Vasopressor Strategy (Adult)

Pharmacology

Prognosis / Complications

• Mortality rises with shock, multiorgan dysfunction, delayed effective antimicrobials, severe comorbidity, and inadequate source control.
• Early reversal of hypotension and improving perfusion markers are favorable signs but do not eliminate risk of later organ dysfunction.
• Acute kidney injury, ARDS, myocardial dysfunction, DIC, and delirium can prolong recovery.
• Post-sepsis syndrome may include weakness, cognitive impairment, anxiety, depression, sleep disturbance, and recurrent hospitalization.
• Recovery planning and follow-up are important components of sepsis care rather than optional afterthoughts.

Patient Education / Counseling

• Explain the infection source when known, the reason for antibiotic changes, and the expected course of organ recovery.
• Patients should understand warning signs for recurrent infection, worsening dyspnea, confusion, fever, low urine output, or inability to maintain hydration.
• Medication reconciliation should include completion or discontinuation dates for antimicrobials and changes to chronic drugs made during organ injury.
• Sepsis survivors may need rehabilitation, nutrition support, cognitive assessment, and primary-care follow-up.
• Review infection-prevention measures such as vaccination, catheter care, wound care, and timely treatment of recurrent urinary or pulmonary symptoms when relevant.
• Families should be told that fatigue and cognitive symptoms can persist even when the original infection has resolved.

Notes

The 2026 Surviving Sepsis Campaign places more emphasis on tailoring antibiotic timing to probability and shock status. This avoids treating every uncertain presentation identically while preserving immediate therapy for the patients in whom delay is most dangerous.

Fluid resuscitation should be iterative. A written 30 mL/kg target is not a substitute for reassessing whether each additional bolus improves perfusion or instead produces venous congestion and pulmonary edema.

References

1. Surviving Sepsis Campaign Adult Guidelines 2026 — Link
2. SCCM Sepsis Resources — Link